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BACKGROUND: Factor V Leiden mutation (Arg506Gln) increases the likelihood of venous thrombosis; it may
also have a positive effect through facilitation of embryo implantation. This may manifest itself as a reduced time
to pregnancy (increased fecundity) and fewer miscarriages in the first trimester. METHODS: From March 1999
onwards, consecutive patients with a first venous thrombosis (VT) were recruited. The first 115 female VT patients
with factor V Leiden and 230 age-matched female VT patients without factor V Leiden were included. All patients,
unaware of their genotype, received a structured questionnaire. RESULTS: Of the 297 (86%) women who
returned the questionnaire, 220 had been pregnant at least once. Time to first pregnancy was unaffected by carrier
status: 58% factor V Leiden carriers reported a pregnancy within 3 months compared to 54% non-carriers. The
miscarriage proportion was 14%, similar in both groups. First trimester miscarriage was less frequent among
carriers (46%) than among non-carriers (95%) (relative risk 0.5, 95% confidence interval 0.3–0.9).
CONCLUSIONS: Factor V Leiden mutation may support embryo implantation, as factor V Leiden carriers had
fewer miscarriages in the first trimester with a similar overall miscarriage rate. Miscarriage of embryos with poor
viability may be postponed until the second trimester in factor V Leiden carriers. Fecundity was not influenced by
factor V Leiden status.
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Introduction
Factor V Leiden mutation (Arg506Gln) is present in 4–10%
of people of Caucasian origin (Bertina et al., 1994; Rees,
1996). The mutation induces a hypercoagulable state which
increases the risk of venous thrombosis 7-fold among hetero-
zygous carriers and ,80-fold among homozygous carriers
compared to non-carriers (Rosendaal et al., 1995). It has
been suggested that factor V Leiden mutation may be associ-
ated with negative outcomes of reproduction such as (recur-
rent) abortion, pre-eclampsia, prematurity and small-
for-gestational-age neonates. However, the available data are
conflicting (Rai et al., 2001; Morrison et al., 2002;
Hundsdoerfer et al., 2003; Pauer et al., 2003). Because of the
high prevalence of this mutation in certain populations, posi-
tive effects associated with factor V Leiden have been postu-
lated, possibly through human reproduction. Women who
carry the factor V Leiden mutation lose less blood in men-
struation, have higher haemoglobin levels, and possibly a
lower incidence of life threatening post-partum haemorrhage,
which could be an evolutionary advantage (Lindqvist et al.,
2001). Furthermore, a higher than expected prevalence of
factor V Leiden mutation carriers was found in healthy preg-
nant women (9.2%) (De Groot et al., 1999) compared to the
general population (3%) (Rosendaal et al., 1995). A similar
finding was reported in a recurrent miscarriage study where
the prevalence of factor V Leiden was higher in women with-
out a history of recurrent miscarriages (14%) compared to
those with recurrent miscarriages (1.7%) (Dilley et al.,
2002). Facilitation of embryo implantation was suggested as
a possible positive pathway for factor V Leiden (Majerus,
1994). In agreement with this hypothesis, an improved
implantation rate in factor V Leiden carriers compared to
non-carriers was reported in ICSI pregnancies. If either the
mother or the fetus carried the factor V Leiden mutation, the
proportion of live births was 90% (9/10) for the first embryo
transfer compared to 49% (45/92) in factor V Leiden nega-
tive pairs (Go¨pel et al., 2001). A reduced time to pregnancy
(increased fecundity) in spontaneous pregnancies of factor V
Leiden carriers would be an indication of a protective effect
of factor V Leiden.
To study the effect of factor V Leiden mutation on embryo
implantation and human reproduction, we investigated
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the association of factor V Leiden mutation on fecundity and
miscarriages and the trimester in which the miscarriages
occurred in 297 women. To be able to construct a large
cohort of women with factor V Leiden, we used information
from a large study on venous thrombosis. We also investi-
gated the effect of factor V Leiden carriership on term birth
rate and birthweight.
Materials and methods
The women described in this study were enrolled in the Multiple
Environmental and Genetic Assessment of risk factors for venous
thrombosis study (MEGA study). The primary aim of the MEGA
study is to assess interaction between environmental and genetic
risk factors for venous thrombosis. From March 1999 onwards, all
consecutive patients who suffered a first deep-vein thrombosis or
pulmonary embolism between the age of 18 and 70 years were
recruited from six anticoagulation clinics in The Netherlands. The
anticoagulation clinics monitor the anticoagulant therapy of all
patients in a well-defined geographical area, which allowed us to
identify consecutive and unselected patients with venous thrombo-
sis. All participants filled in a questionnaire on risk factors for
venous thrombosis. A blood sample was drawn 3 months after dis-
continuation of anticoagulation therapy. Subjects who were unable
or declined to give a blood sample were given the opportunity to
give DNA by use of a buccal swab. All participants completed an
informed consent form. The Leiden University Medical Center
medical ethics committee approved the study.
For the present analysis, the first 115 female thrombosis patients
identified with factor V Leiden mutation were matched by age to
230 female thrombosis patients (controls). Besides the age matching
and absence of factor V Leiden, controls were randomly selected
from the study participants. All 345 patients, who were unaware of
their genotype, were asked to fill in an additional structured ques-
tionnaire concerning their reproductive history. Questions consisted
of age at first pregnancy attempt, the period of unprotected inter-
course until the desired pregnancy occurred, number of pregnancies,
and the duration of each pregnancy. When there had been no preg-
nancies, we enquired whether this was despite efforts to become
pregnant (infertility). If there was no response to the initial question-
naire, a written reminder accompanied with an identical question-
naire was sent after 3 weeks. To increase response, patients were
contacted by telephone if they did not return the questionnaire after
an additional 5 weeks.
Time to pregnancy was defined as self-reported time between
unprotected intercourse and the occurrence of pregnancy. Miscar-
riage ratio was calculated as the total number of miscarriages per
number of pregnancies. First trimester miscarriage was defined as
embryonic or fetal loss before the completion of 12 weeks gestation;
second trimester miscarriage was defined as fetal loss from 13 to
24 weeks gestation; stillbirth was defined as a loss after 24 weeks
gestation. A number of factors known to influence miscarriage or
fecundity were included in the questionnaire, such as age at first
pregnancy attempt, age at first birth, level of education (primary
school, secondary school, college or university), smoking habits,
and alcohol use. The body mass index [BMI: weight in kg/(height in
m)2] was calculated at the time of thrombosis.
DNA was isolated from whole blood or buccal swabs. For the
latter, three large cotton swabs in a total of 6 ml sodium dodecyl
sulphate–proteinase K solution (100 mmol/l NaCl, 10 mmol/l
EDTA, 10 mmol/l Tris–HCl pH 8.0, 0.5% SDS, 0.1 mg/ml protein-
ase K) were obtained from each patient. Upon arrival, the proteinase
K concentration was raised to 0.2 mg/ml and the sample was incu-
bated for 2 h at 658C. Subsequently, the suspension was recovered
by centrifugation. Potassium acetate was added to a final concen-
tration of 1.6 mol/l. After 15 min incubation on ice, proteins were
removed using chloroform–isoamylalcohol (24:1) treatment. The
DNA in the water phase was subsequently ethanol-precipitated.
After centrifugation, the pellet was resuspended in 200 ml 10 mmol/l
Tris–HCl, 10 mmol/l EDTA pH 8.0 and frozen at 2208C until
further analysis. Assessment of the factor V Leiden mutation in
DNA retrieved from the buccal swabs was performed identically to
the method for DNA from whole blood, and determined by PCR
and Mnl I restriction digestion as described elsewhere (Bertina et al.,
1994).
Data are presented as simple counts and percentages. Relative
risks (RR) were computed as the ratio of these counts, and 95%
confidence intervals (CI) were based on a binomial distribution.
Results
A total of 297 (86%) women returned a completed question-
naire: 89% of the factor V Leiden carriers and 84% of the
non-carriers. Of the 48 non-responders, four women were
deceased, six were lost to follow-up, and for 21 women the
reason for not returning the questionnaire was unknown.
Seventeen questionnaires were returned blank because of:
lack of motivation (four women), three women were too ill,
for two women it brought back too many painful memories
(both non-carriers), and in eight cases no reasons were given.
Of the 102 factor V Leiden carriers who returned the com-
pleted questionnaire, 80 (78%) had been pregnant at least
once compared to 140 (72%) of the 195 non-carriers (RR
1.1, 95% CI 0.95–1.2). Patient characteristics of these 220
women are listed in Table I. The reasons for not having had
a pregnancy were similar; infertility was reported by 5%
(1/22) of factor V Leiden carriers and 11% (6/55) of non-
carriers (RR 0.4, 95% CI 0.1–3.3).
Time to first pregnancy was similar for factor V Leiden
carriers and non-carriers. In both groups, .90% of those
Table I. Patient characteristics and reproductive outcome of the 220 women
who had been pregnant, according to factor V Leiden carrier status
Factor V Leiden
carriera (n ¼ 80)
Factor V Leiden
non-carrier (n ¼ 140)
Age at thrombosis (years) 45.1 (20–68) 44.4 (20–70)
Age at questionnaire (years) 47.6 (23–71) 46.8 (23–72)
Menstrual cycle, regular 66 (84) 118 (84)
Education, college/university 32 (45) 52 (43)
Smoked, ever 50 (63) 77 (55)
Body mass index (kg/m2) 27 (18–58) 27 (17–57)
Age at first pregnancy
attempt (years)
24.1 (15–36) 24.1 (15–38)
Age at birth first child (years) 25.2 (16–36) 25.3 (15–39)
No. of pregnancies 2.2 2.7
No. of liveborn children 1.7 1.9
Total no. of miscarriages 25 (14) 50 (14)
Stillbirths 2 (1) 9 (2)
Ectopic pregnancies 0 (2) 4 (1)
Planned abortion 10 (6) 17 (4)
Other (e.g. twins) 4 (2) 9 (2)
Values are mean (range) or n (%).
aOne homozygous factor V Leiden mutation carrier.
Factor V Leiden, miscarriage and venous thrombosis
803
who had been pregnant could recall the time to their first
pregnancy. Forty-two (58%) factor V Leiden carriers
achieved their first pregnancy within 3 months compared to
70 (54%) of the non-carriers (RR 1.1, 95% CI 0.8–1.4). Nine
(13%) factor V Leiden carriers reported a time to first preg-
nancy of .12 months, which had occurred in 21 (16%) of
the non-carriers (RR 0.8, 95% CI 0.4–1.6). When all
consecutive pregnancies per woman were combined, similar
results were found (Figure 1).
The miscarriage proportion for all pregnancies was simi-
lar in both groups, 14% (25/179) for factor V Leiden
carriers and 14% (50/365) for non-carriers (RR 1.0, 95%
CI 0.6–1.6). Considering only the first pregnancy, 16%
(13/80) of the factor V Leiden carriers had experienced a
miscarriage compared to 15% (21/140) of the non-carriers
(RR 1.1, 95% CI 0.6–2.0). However, the trimester in
which the miscarriages occurred was different according to
factor V Leiden status; factor V Leiden carriers who
experienced a miscarriage during their first pregnancy had
fewer miscarriages in the first trimester compared to non-
carriers, respectively 46 and 95% (RR 0.5, 95% CI:
0.3–0.9). Subsequently, factor V Leiden carriers had more
miscarriages in the second trimester (RR 10.8, 95% CI
1.5–77.7) (Table II). When all consecutive pregnancies per
woman were combined, the difference persisted (Table II).
Stillbirth (fetal loss in the third trimester) was rare, and
was equal in both groups. For the 80 first pregnancies of
factor V Leiden carriers, no stillbirths occurred compared
to four (3%) stillbirths in 140 first pregnancies in non-
carriers. For all pregnancies per woman combined, two
(1%) stillbirths occurred in 179 pregnancies in factor V
Leiden carriers compared to nine (2%) in 365 pregnancies
in non-carriers (RR 0.4, 95% CI 0.1–2.1).
The proportion of live births was similar in both groups;
74% (59/80) among factor V Leiden carriers compared to
76% (106/140) among non-carriers (RR 1.0, 95% CI 0.8–
1.1). Term birth (37–42 weeks gestation) in first pregnancies
was comparable, 64% (38/59) and 69% (73/106) respectively
(RR 0.9, 95% CI 0.7–1.2). Mean birthweight for the children
born at term was similar for factor V Leiden carriers (3644 g,
range 2500–4000) and non-carriers (3481 g, range 1200–
3975).
Discussion
In this study of 297 women with venous thrombosis, we
found no association between factor V Leiden mutation and
fecundity or the frequency of miscarriage. However, when
miscarriages had occurred, they took place less often in the
first trimester in factor V Leiden mutation carriers than in
non-carriers.
Miscarriages occurred as often in factor V Leiden carriers
(14%) and non-carriers (14%), in percentages that are similar
to the general population (10–15%) (Zinaman et al., 1996).
Published data on factor V Leiden in relation to miscarriages
are conflicting. Recent meta-analyses have shown an associ-
ation between factor V Leiden and recurrent fetal loss, occur-
ring both in early and in late in gestation (respectively OR
2.01, 95% CI 1.13–3.58 and OR 7.83, 95% CI 2.83–21.67)
(Rey et al., 2003; Kovalevsky et al., 2004). For non-recurrent
early loss (,19 weeks gestation) no clear association was
found with factor V Leiden (OR 1.40, 0.66–2.97); and for
non-recurrent isolated second/third trimester loss (stillbirth
.19 weeks) a positive association was found (OR 3.26, 95%
CI 1.82–5.83) (Rey et al., 2003; Dudding and Attia, 2004).
The focus in the literature has mainly been on factor V
Leiden in relation to second and third trimester loss, as
thrombosis of the placental vessels is assumed to be an
important factor in fetal loss. In our study, factor V Leiden
carriers experienced more fetal loss in the second trimester,
as would be expected by the placental vessel thrombosis
theory. A clear increase in third trimester loss would also be
expected, with an even higher rate of fetal loss in third than
in second trimester for factor V Leiden carriers. However,
third trimester loss (stillbirth) was equally distributed over
carriers and non-carriers, with a similarly low rate, which
contradicts this theory. Moreover, in the present study, mean
birthweight was not influenced by factor V Leiden status,
which is in line with earlier published data (Lindqvist et al.,
1999). If we consider hypercoagulability to lead to obstruc-
tion of placental vessels as a major pathological factor
Figure 1. Fecundity (time to pregnancy) for all pregnancies in 220
venous thrombosis patients according to factor V Leiden mutation
(179 pregnancies in factor V Leiden carriers and 365 pregnancies in
non-carriers, number of pregnancies stated in the bars).
Table II. Miscarriages, per trimester, out of 220 women who had been
pregnant, according to factor V Leiden (FVL) mutation
First trimester
(#12 weeks)
Second trimester
(13–24 weeks)
Total
First pregnancy only (80 pregnancies in FVL carriers and 140 in non-
carriers)
FVLþ 6 (46) 7 (54) 13
FVL2 19 (95) 1 (5) 20a
Relative risk (95% CI) 0.5 (0.3–0.9) 10.8 (1.5–77.7)
All pregnancies combined (179 in FVL carriers and 365 in non-carriers)
FVLþ 16 (64) 9 (36) 25
FVL2 43 (90) 5 (10) 48b
Relative risk (95% CI) 0.7 (0.5–1.0) 3.5 (1.3–9.2)
Values are n (%).
aOf one non-carrier, the trimester in which the miscarriage took place was
unknown.
bOf two non-carriers, the trimester in which the miscarriage took place was
unknown.
CI ¼ confidence interval.
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among pregnant factor V Leiden carriers, one would not
expect an effect on first trimester miscarriages, since the pla-
cental circulation in the first trimester has not yet been fully
established (Hustin and Schaaps, 1987; Burton et al., 1999).
Therefore, impaired placental perfusion might not be critical
for the embryonic development and implantation during
(very) early gestation. We cannot differentiate between the
types of early pregnancy loss in this study (e.g. presence or
absence of fetal heart prior to the loss), as all the data were
provided to us by the patients through interview. Further-
more, most would not have had an early first trimester scan,
as they are not routinely done in The Netherlands.
Our results indicate a clear reduction in first trimester loss
in factor V Leiden carriers, which is subsequently compen-
sated by an increased loss in the second trimester. Similar
findings were reported in a recent study where a decreased
risk of recurrent pregnancy losses at ,10 weeks gestation
was found in factor V Leiden carriers (OR 0.23, 95% CI
0.07–0.77) with a subsequent increase in losses after 10
weeks (Roque´ et al., 2004). This suggests a protective effect
on the embryo during the first trimester in factor V Leiden
carriers, including less viable embryos that will eventually
abort in the second trimester. This may explain the similar
overall frequency of miscarriages in factor V Leiden carriers
and non-carriers. A lower frequency of miscarriages in the
first trimester may thus reflect a successful implantation.
Approximately 50–70% of all miscarriages are attributable
to detectable chromosomal abnormalities, furthermore 15–
20% is thought to be due to morphological defect(s) in the
embryo. A recent study confirmed this with a transcervical
embryoscopy at the time of the curette and cytogenetic analy-
sis of the products of conception (Philipp et al., 2003). We
have no cytogenetic information in our study, as karyotyping
of the products of conception is not a routine consideration
in The Netherlands. The possible protective effect of factor
V Leiden early in pregnancy will require further study with,
among other things, cytogenetic testing of the miscarriage
products and possibly transcervical embryoscopy prior to
evacuation.
Our study did not show a clearly increased fecundity in
factor V Leiden carriers. Many factors affect fecundity,
including physiological, behavioural and environmental fac-
tors. Known factors, such as age at pregnancy attempt, regu-
larity of the menstrual cycle, smoking habits and educational
level were similar in factor V Leiden carriers and non-car-
riers. As fecundity is a manifestation of both conception and
implantation, it is important to further distinguish these. For
conception, factors such as sperm quality, coital frequency
and timing are of great importance. However, this study was
not designed to examine these factors and it remains unclear
whether factor V Leiden has any effect on these factors.
Aspects influencing implantation have not yet been fully elu-
cidated; however, improved implantation could be due to an
increase in the hypercoagulable state, related to the factor V
Leiden mutation. This was suggested by a study that omitted
conception by reporting only on ICSI pregnancies, reflecting
implantation success (Go¨pel et al., 2001). A higher incidence
of implantation success was found if either the mother or the
fetus was a factor V Leiden carrier. It is possible that the
beneficial effect of factor V Leiden on implantation alone
has a less clear affect on fecundity compared to various fac-
tors concerning conception, and therefore, in our study, fails
to show an overall difference in fecundity.
We investigated the reproductive histories of women who
had suffered venous thrombosis. The choice of this design
was opportunistic, in that it offered the opportunity to study a
large cohort of factor V Leiden carriers. We have considered
whether this choice, rather than the ideal study of factor V
Leiden carriers without thrombosis, could have distorted our
results. First, the period about which questions were asked
preceded the thrombotic event, in most cases by many years.
Hence, the thrombotic event itself did not influence our
results. As the patients developed thrombosis, they will have
had more risk factors for thrombosis than other women. It is
known that this is not only true for women without factor V
Leiden but also for women with factor V Leiden (the
majority of people with factor V Leiden never develop
thrombosis, and there must be causes why some do). For this
reason, we chose thrombosis cases without factor V Leiden
as controls rather than healthy women without factor V
Leiden, and therefore differences between the group can be
attributed to factor V Leiden. One could argue that the
groups differed more: women with thrombosis without factor
V Leiden probably had more additional risk factors than
those with factor V Leiden, for instance another, possibly
still unknown, gene defect. This could, if that other pro-
thrombotic factor also affected implantation and fetal loss,
explain the absence of a difference between the groups in the
frequency of miscarriage. However, we did find a difference.
As the reproductive data in the present study were col-
lected by interview, recall bias is possible, but seems unli-
kely. Validation studies of fecundity and miscarriages have
shown a good match between long-term recall of personal
reproductive history through interview and medical data
(Joffe et al., 1993). Moreover, the women were unaware of
their factor V Leiden status at the time of the questionnaire.
In conclusion, factor V Leiden mutation may support
embryo implantation, as factor V Leiden carriers reported
significantly fewer miscarriages in the first trimester. This
was not reflected in an increased fecundity. The overall mis-
carriage proportion was not influenced by factor V Leiden
status. These results suggest that factor V Leiden offers a
protective effect on early pregnancy and that the miscarriage
of embryos with poor viability in factor V Leiden carriers is
postponed until the second trimester.
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